Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Winograd · SciRah

Researcher profile · Semantic Scholar

B. Winograd

Share profile

B. Winograd — researcher profile on SciRah

h-index: 23
Works: 67
Citations: 3,041

Most-cited papers

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
P. McCarthy, S. Holstein, M. Petrucci, P. Richardson +15 more
2017Journal of Clinical Oncology607 citations Open access
Semantic Scholar
Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing.
Y. Keepers, P. Pizão, G. Peters, J. van Ark-Otte +2 more
1991European Journal of Cancer464 citations Open access
Semantic Scholar
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
J. Nabholtz, K. Gelmon, M. Bontenbal, M. Spielmann +7 more
1996Journal of Clinical Oncology400 citations
Semantic Scholar
Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma.
Parkash S. Gill, A. Tulpule, B. Espina, S. Cabriales +8 more
1999Journal of Clinical Oncology183 citations
Semantic Scholar
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
José Saura-Esteller, Milon de Jong, L. King, E. Ensing +4 more
2022Frontiers in Immunology178 citations Open access
Semantic Scholar
Promising new developments in cancer chemotherapy
K. Ferrante, B. Winograd, R. Canetta
1999Cancer Chemotherapy and Pharmacology96 citations
Semantic Scholar
Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.
E. Boven, B. Winograd, D. Berger, M. Dumont +4 more
1992Cancer Research93 citations
Semantic Scholar
Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
M. B. van Hennik, W. V. D. van der Vijgh, I. Klein, F. Elferink +3 more
1987Cancer Research93 citations
Semantic Scholar
Overview of Taxol safety.
N. Onetto, R. Canetta, B. Winograd, R. Catane +4 more
1993Journal of the National Cancer Institute. Monographs86 citations
Semantic Scholar
Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.
Luca Gianni, P. Dombernowsky, G. Sledge, Miguel Martin +8 more
2001Annals of Oncology78 citations Open access
Semantic Scholar
Phase I and clinical pharmacological evaluation of aphidicolin glycinate.
C. Sessa, M. Zucchetti, E. Davoli, R. Califano +6 more
1991Journal of the National Cancer Institute58 citations
Semantic Scholar
Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (review).
B. Winograd, E. Boven, M. Lobbezoo, H. Pinedo
1987In Vivo55 citations
Semantic Scholar
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
J. Vermorken, W. W. ten Bokkel Huinink, I. Mandjes, T. Postma +6 more
1995Seminars in Oncology48 citations
Semantic Scholar
Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction.
R. Lippens, B. Winograd
1988Pediatric Hematology & Oncology46 citations
Semantic Scholar
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
R. Lameris, J. Ruben, Victoria Iglesias-Guimarais, Milon de Jong +13 more
2023Cell Reports Medicine42 citations Open access
Semantic Scholar
Preclinical phase II studies in human tumor lines: a European multicenter study.
E. Boven, B. Winograd, O. Fodstad, M. Lobbezoo +1 more
1988European Journal of Cancer and Clinical Oncology39 citations Open access
Semantic Scholar
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
D. Bota, W. Mason, S. Kesari, R. Magge +6 more
2021Neuro-Oncology Advances37 citations Open access
Semantic Scholar
Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates.
Paulo E. Pizao, D. Lyaruu, Godefridus J. Peters, J. van Ark-Otte +3 more
1992British Journal of Cancer34 citations Open access
Semantic Scholar
Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures.
Paulo E. Pizao, G. Peters, J. van Ark-Otte, L. A. Smets +4 more
1993European Journal of Cancer33 citations Open access
Semantic Scholar
Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
R. D. de Jong, N. Mulder, D. Uges, S. Kaul +6 more
1997British Journal of Cancer29 citations Open access
Semantic Scholar
The main steps in the development of anticancer agents.
G. Schwartsmann, B. Winograd, H. Pinedo
1988Radiotherapy and Oncology29 citations Open access
Semantic Scholar
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies
G. Schwartsmann, P. Dodion, J. Vermorken, W. W. ten Bokkel Huinink +8 more
2004Cancer Chemotherapy and Pharmacology28 citations Open access
Semantic Scholar
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Guy G. Chabot, J. Armand, C. Terret, M. de Forni +7 more
1996Journal of Clinical Oncology26 citations
Semantic Scholar
Paclitaxel plus carboplatin in the treatment of ovarian cancer.
W. W. ten Bokkel Huinink, C. Veenhof, T. Helmerhorst, F. Bierhorst +4 more
1995Seminars in Oncology19 citations
Semantic Scholar
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
G. Schwartsmann, W. V. D. van der Vijgh, M. B. van Hennik, I. Klein +9 more
1989European Journal of Cancer and Clinical Oncology19 citations Open access
Semantic Scholar
Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC).
N. Mehra, D. Robbrecht, J. Voortman, P. Parren +6 more
2023Journal of Clinical Oncology18 citations Open access
Semantic Scholar
Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.
W. W. ten Bokkel Huinink, C. Veenhof, M. Huizing, S. Rodenhuis +5 more
1997Seminars in Oncology17 citations
Semantic Scholar
Drug discovery and development in the pharmaceutical industry.
Lee P. Schacter, Cheryl Anderson, Renzo Canetta, Susan Kelley +5 more
1992Seminars in Oncology14 citations
Semantic Scholar
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
David Porter, Alan V. Boddy, Huw D. Thomas, Michael J. Lind +6 more
1996Seminars in Oncology13 citations
Semantic Scholar
Renal excretion and pharmacokinetics of methotrexate and 7-hydroxy-methotrexate following a 24-h high dose infusion of methotrexate in children
B. Winograd, R. Lippens, M. Oosterbaan, M. Dirks +2 more
2004European Journal of Clinical Pharmacology12 citations
Semantic Scholar
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481).
M. Millward, D. R. Newell, Vanaja Mummaneni, Linus N. Igwemezie +14 more
1995European Journal of Cancer12 citations Open access
Semantic Scholar
Human Tumour Xenografts in Anticancer Drug Development
B. Winograd, M. Peckham, H. Pinedo
1988ESO Monographs12 citations
Semantic Scholar
Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data
A. Kater, N. V. van de Donk, P. Rodríguez-Otero, M. Mateos +10 more
2022Blood11 citations Open access
Semantic Scholar
Taxol: initial Israeli experience with a novel anticancer agent.
A. Sulkes, U. Beller, Tamar Peretz, J. Shacter +3 more
1994Israel journal of medical sciences11 citations
Semantic Scholar
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
W. Mason, S. Kesari, R. Stupp, D. Aregawi +9 more
2019Journal of Clinical Oncology10 citations
Semantic Scholar
A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results.
D. Bota, S. Kesari, D. Piccioni, D. Aregawi +9 more
20189 citations
Semantic Scholar
Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
B. Winograd, J. Vermorken, W. W. ten Bokkel Huinink, G. Simonetti +5 more
1986Cancer Research8 citations
Semantic Scholar
P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES
A. Broijl, N. W. van de Donk, F. Bosch, M. Mateos +10 more
2022HemaSphere7 citations Open access
Semantic Scholar
LOW DOSE PACLITAXEL (TAXOL⊙) IS HIGHLY EFFECTIVE IN THE TREATMENT OF PATIENTS WITH ADVANCED AIDS-RELATED KAPOSI'S SARCOMA: 77
P. Gill, D. Scadden, J. Groopman, A. Tulpule +9 more
19977 citations Open access
Semantic Scholar
924 Pharmacology of paclitaxel (P) and metabolites in patients with altered liver function
M. Huizing, H. Rosing, J. Vermorken, A. de Graeff +4 more
19957 citations
Semantic Scholar
ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)
D. Bota, A. Desjardins, W. Mason, S. Kesari +5 more
20176 citations Open access
Semantic Scholar
Phase I study of the mitomycin C analogue BMS-181174.
V. Macaulay, K. O'Byrne, John Green, Philip A. Philip +6 more
1998British Journal of Cancer5 citations Open access
Semantic Scholar
In vitro chemosensitivity testing of multilayered microcultures.
P. Pizão, B. Winograd, Godefridus J. Peters, A. Leyva +2 more
1992Anticancer Research5 citations
Semantic Scholar
Proposal for the Application of Xenografts in Screening for New Anticancer Agents and in Selecting Tumor Types for Phase II Clinical Trials
B. Winograd, M. Lobbezoo, H. Pinedo
19885 citations
Semantic Scholar
Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
F. Elferink, W. V. D. van der Vijgh, W. W. ten Bokkel Huinink, J. Vermorken +7 more
1987British Journal of Cancer5 citations Open access
Semantic Scholar
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters
V. Mummaneni, S. Kaul, Linus N. Igwemezie, D. Newell +5 more
1996Journal of pharmacokinetics and biopharmaceutics4 citations Open access
Semantic Scholar
Determination of sparsomycin in plasma and urine of the dog by means of reversed-phase high-performance liquid chromatography and first pharmacokinetic results.
B. Winograd, M. Oosterbaan, E. van der Kleijn, R. Liskamp +2 more
1983Journal of Chromatography A4 citations
Semantic Scholar
Pharmacokinetics and toxicology of sparsomycin in beagle dogs
Z. Żylicz, D. J. Theo Wagener, P. F. del Moral, H. van Rennes +7 more
2004Cancer Chemotherapy and Pharmacology3 citations
Semantic Scholar
Phase I study of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies
C. Sessa, M. Highley, O. Pagani, R. Plummer +6 more
19993 citations Open access
Semantic Scholar
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
A. Planting, J. Schellens, M. V. D. van der Burg, M. de Boer-Oennert +3 more
1999Anti-Cancer Drugs3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Pinedo×11
Invite
H. Pinedo — researcher profile on SciRah
W. W. ten Bokkel Huinink×7
Invite
W. W. ten Bokkel Huinink — researcher profile on SciRah
J. Vermorken×6
Invite
J. Vermorken — researcher profile on SciRah
P. Parren×5
Invite
P. Parren — researcher profile on SciRah

H. J. van der Vliet

×5

Invite

H. J. van der Vliet — researcher profile on SciRah

W. V. D. van der Vijgh×5

Invite

W. V. D. van der Vijgh — researcher profile on SciRah

Invite

H. Pinedo — researcher profile on SciRah

Invite

D. Bota — researcher profile on SciRah

Invite

W. Mason — researcher profile on SciRah

Invite

S. Kesari — researcher profile on SciRah

Invite

S. Reich — researcher profile on SciRah

Invite

N. Levin — researcher profile on SciRah